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Chronic ConstipationThroughout history, bowel irregularity has been perceived as detrimental to health. The oldest
complete medical text in existence is an Egyptian pharmaceutical papyrus from the 16th century BC,
that offers as a basic explanation of disease, the notion that the body is poisoned by material released
from decomposing waste in the intestines [1]. Jump forward to 2011, and despite its high prevalence
(w15% in adults andw9% in children) [2,3] and huge burden on healthcare resources (in the US alone
in 2004, a primary complaint of constipation was responsible for 6.3 million patient visits to medical
care centres, resulting in total costs of $1.7 billion) [4], our understanding of the pathophysiology of
constipation, both in paediatric and adult populations remains primitive [5]. Accordingly, current
therapies are ineffective in a substantial number of patients, leading to school absenteeism, high
number of days off work, and social regression.
In this issue of Best Practice & Research: Clinical Gastroenterology, experts in the ﬁeld of paediatric
and adult gastroenterology present up-to-date reviews on all aspects regarding chronic constipation.
Epidemiology, impact on quality of life, and the coexistence of constipation and faecal incontinence are
covered in separate chapters, as well as contemporary insights into pathophysiological mechanisms
underlying constipation, including neuromuscular pathology, use of animal models, genetic inﬂuences,
and also novel in vivo human studies. An update on the newest diagnostic tests available for the
evaluation of colorectal function is also provided. Fundamentally, given the chronicity of the condition
in all different age groups, the development and evaluation of novel treatments are of major impor-
tance. In view of this, new drug therapies, surgical indications and sacral neuromodulation are also
described in detail; hopefully, these will lead to better management of some of these therapy-resistant
patients.
References
[1] Ebbell BB, editor. The Papyrus Ebers. Copenhagen, Denmark: Levin and Munksgaard; 1937. p. 30–2.
[2] McCrea GL, Miaskowski C, Stotts NA, et al. A review of the literature on gender and age differences in the prevalence and
characteristics of constipation in North America. J. Pain. Symptom. Manage. 2009;37:737–45.
[3] van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am. J. Gas-
troenterol. 2006;101:2401–9.
[4] Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases.
Gastroenterology 2009;136:376–86.
[5] Cook IJ, Talley NJ, Benninga MA, et al. Chronic constipation: overview and challenges. Neurogastroenterol. Motil. 2009;21
(Suppl. 2):1–8.
M.A. Benninga, MD, PhD, Head of Department
Department of Pediatric Gastroenterology and Nutrition,
Emma Children’s Hospital, Academic Medical Centre, Amsterdam, The Netherlands1521-6918  2011 Elsevier Ltd.
doi:10.1016/j.bpg.2011.01.002
Open access under the Elsevier OA license.
Preface / Best Practice & Research Clinical Gastroenterology 25 (2011) 1–22S.M. Scott, PhD, Senior Clinical Scientist & Director, GI Physiology Unit*
Academic Surgical Unit & Neurogastroenterology Group, Barts and The London
School of Medicine and Dentistry, Queen Mary University London, United Kingdom
 Corresponding author. Tel.: þ44 20 7377 7194; fax: þ44 20 7377 7346.
E-mail address: m.scott@qmul.ac.uk.
